Neuro-Bio Limited is taking a new approach to neurodegenerative disorders such as Alzheimer’s Disease. Founded on 40 years of original neuroscience research we were the first to identify a novel signaling molecule (a peptide ‘T14’) which is significantly elevated in Alzheimer’s brains and drives the cycle of brain cell death in selectively vulnerable cells. As a consequence, it is T14 that is the primary trigger for the production of beta-amyloid and tau which are thus secondary, downstream phenomena. Based on this discovery, Neuro-Bio is developing a system for detection of T14 as a companion biomarker for early diagnosis of neuro-degenerative disorders along with novel drug candidates (NBP14 and variants) that could be a completely different type of drug to actually halt the neurodegenerative process.
Founded in 2013, Neuro-Bio is a privately held company based near Oxford, UK. Its primary business focus is the translation, out-licensing and commercialisation of its innovative first in class products to address major unmet medical needs relating to neuro-degenerative conditions. The company has a pipeline of future products that includes other indications such as Parkinson’s and Motor Neurone Disease.